- Home
- KRNY vs BCYC Comparison
KRNY vs BCYC Comparison
Compare KRNY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRNY | BCYC |
|---|---|---|
| Founded | 1884 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.5M | 456.4M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KRNY | BCYC |
|---|---|---|
| Price | $8.21 | $5.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $8.00 | ★ $19.10 |
| AVG Volume (30 Days) | 366.5K | ★ 371.0K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | ★ 130.22 | 42.91 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $27.08 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.45 | $5.03 |
| 52 Week High | $8.50 | $11.81 |
Technical Indicators
Market Signals| Indicator | KRNY | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 37.09 |
| Support Level | $7.99 | $5.03 |
| Resistance Level | $8.33 | $5.57 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 55.36 | 22.78 |
Price Performance
Historical ComparisonAbout KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.